Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Advanced Breast Cancer Therapies, and Cancer Immunotherapy and Biomarkers.
Supplementary Table S1: Exploratory analysis of ORR by clinical and demographic subgroups from FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations
Data from FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations
Evaluation of somatic copy number variation detection by NGS technologies and bioinformatics tools on a hyper-diploid cancer genome
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.
Data from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Supplementary Table S2 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Supplementary Table S1 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Data from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Supplementary Table S2 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Supplementary Table S1 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer.
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease.
Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases
Advancing Drug Development in Gynecologic Malignancies
Ki-67 is required for maintenance of cancer stem cells but not cell proliferation